Core Insights - Oncolytics Biotech Inc. announced the acceptance of two abstracts for presentation at the 2025 ASCO Gastrointestinal Cancers Symposium, highlighting the potential of pelareorep in treating difficult gastrointestinal cancers [1][2] Company Overview - Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that has shown promising results in various cancer studies [3][4] - Pelareorep works by inducing anti-cancer immune responses and converting "cold" tumors into "hot" tumors, enhancing the effectiveness of existing cancer treatments [3] Clinical Data Presentation - The first abstract, titled "GOBLET platform study," will present preliminary safety and tumor response results for relapsed anal carcinoma patients treated with pelareorep and atezolizumab, scheduled for January 25, 2025 [2] - The second abstract, titled "GOBLET study," will discuss safety run-in results for first-line metastatic pancreatic ductal adenocarcinoma patients treated with pelareorep combined with modified FOLFIRINOX and/or atezolizumab, scheduled for January 24, 2025 [2] Regulatory and Clinical Development - Oncolytics is advancing towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA [4]

Condensed Interim Consolidated Financial Statements (unaudited) Oncolytics Biotech Inc. For the three and nine months ended September 30, 2024 ® ONCOLYTICS BIOTECH INC. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (unaudited) (in thousands of Canadian dollars, except share amounts) | --- | --- | --- | --- | --- | |-----------------------------------------------------------------------------------------------------------------------------------------------|-------|----------------------|-- ...

BRACELET-1 data showing impressive overall survival benefit in HR+/HER2- metastatic breast cancer affirms pelareorep + paclitaxel combination should be evaluated in a registrational studyUpcoming GOBLET milestones include updated efficacy data from anal cancer cohort and safety run-in data from the modified FOLFIRINOX pancreatic cancer cohortCash position of $19.6 million as of September 30, 2024Management hosting conference call and webcast today at 8:30 a.m. ETSAN DIEGO and CALGARY, AB, Nov. 12, 2024 /PRN ...

Company Overview - Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously delivered immunotherapeutic agent [3] - Pelareorep has shown promising results in clinical studies for metastatic breast cancer and pancreatic cancer, inducing anti-cancer immune responses and converting "cold" tumors to "hot" tumors [3][4] Upcoming Events - Oncolytics will host a conference call and webcast on November 12, 2024, at 8:30 a.m. ET to discuss corporate updates and financial results for Q3 2024 [1][2] Clinical Development - The company is conducting and planning combination clinical trials with pelareorep in various solid and hematological malignancies, advancing towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA [4]

Shares of Oncolytics Biotech (ONCY) rallied 18.2% on Friday after the company announced that it is seeking an accelerated pathway for the approval of its lead developmental candidate, pelareorep, for the metastatic breast cancer (mBC) indication. The stock is also gaining today. Pelareorep follows a unique mechanism of action, different from currently available therapeutics for this indication. It selectively targets cancer cells, triggering a cascade of inflammatory responses (which include PDL1 upregulati ...

Recent clinical efficacy results from the BRACELET-1 trial in HR+/HER2- breast cancer pave the way for a clinical study designed to support an accelerated approval Key milestones in gastrointestinal cancer clinical trials expected in 2025, with potential for new registrationenabling studies SAN DIEGO and CALGARY, AB, Oct. 4, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, is issuing a corporate update to pr ...

Overall survival (OS) results from BRACELET-1 corroborate results of previous randomized IND-213 breast cancer study Together, these two studies support the compelling potential of pelareorep-based combination therapy to benefit patients with advanced or metastatic HR+/HER2- breast cancer Oncolytics Biotech is moving forward to secure funding for a registration-enabling study of pelareorepbased therapy in advanced or metastatic breast cancer Over half of BRACELET-1 patients in the pelareorep + chemotherapy ...

SAN DIEGO and CALGARY, AB, Sept. 6, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that Chief Financial Officer Kirk Look will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference, which is taking place September 9-11, 2024 at the Lotte New York Palace Hotel in New York, NY. Chief Medical Officer Tom Heineman, M.D., Ph.D., will participate in a fire ...

SAN DIEGO and CALGARY, AB, Aug. 2, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that Chief Medical Officer Dr. Thomas Heineman will participate in a fireside chat at Canaccord Genuity's 44th Annual Growth Conference, which is taking place August 13-15, 2024 at the InterContinental Boston Hotel in Boston, MA. Additional details on the fireside chat can be found below. Date: Tuesday, August ...

Condensed Interim Consolidated Financial Statements (unaudited) Oncolytics Biotech Inc. For the three and six months ended June 30, 2024 ® ONCOLYTICS BIOTECH INC. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (unaudited) (in thousands of Canadian dollars, except share amounts) | | | June 30, | | December 31, | | --- | --- | --- | --- | --- | | As at | | 2024 | | 2023 | | Assets | | | | | | Current assets | | | | | | Cash and cash equivalents (note 4) | $ | 24,850 | $ | 34,912 | | Other rec ...